 NetScientific PLC AIM:NSCI says its portfolio company, PDS Biotechnology Corporation NASDAQ:PDSB Nasdaq: PDSB, made good progress through 2021, hitting a number of milestones. Ilian Iliev, NetScientific chief executive, said: PDS has continued the steady progress and build-out of the business, progressing multiple clinical applications of the Versamune platform in immuno-oncology and infectious disease vaccines. 